NR1H4 and primary biliary cholangitis: In 2016, obeticholic acid (OCA), a highly selective agonist of FXR, was approved by the U.S. Food and Drug Administration for treatment of primary biliary cholangitis (PBC), a chronic cholestatic liver disease.